KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $618.7 million.

  • Royalty Pharma's Cash & Equivalents fell 3340.38% to $618.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $618.7 million, marking a year-over-year decrease of 3340.38%. This contributed to the annual value of $618.7 million for FY2025, which is 3340.38% down from last year.
  • Latest data reveals that Royalty Pharma reported Cash & Equivalents of $618.7 million as of Q4 2025, which was down 3340.38% from $938.9 million recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Cash & Equivalents peaked at $2.2 billion during Q2 2023, and registered a low of $477.0 million during Q4 2023.
  • In the last 5 years, Royalty Pharma's Cash & Equivalents had a median value of $1.0 billion in 2022 and averaged $1.3 billion.
  • As far as peak fluctuations go, Royalty Pharma's Cash & Equivalents skyrocketed by 89820.95% in 2021, and later crashed by 7211.69% in 2023.
  • Over the past 5 years, Royalty Pharma's Cash & Equivalents (Quarter) stood at $1.5 billion in 2021, then increased by 11.01% to $1.7 billion in 2022, then crashed by 72.12% to $477.0 million in 2023, then skyrocketed by 94.76% to $929.0 million in 2024, then plummeted by 33.4% to $618.7 million in 2025.
  • Its last three reported values are $618.7 million in Q4 2025, $938.9 million for Q3 2025, and $631.9 million during Q2 2025.